Randomized Trialhigh evidence
Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naive Patients.
Circulation·May 15, 2026·PMID 42137960
Why it mattersCurrent PCSK9 inhibitors require injection, limiting access and adherence. An effective oral option could expand lipid-lowering therapy for patients who need additional LDL-C reduction beyond statins, potentially improving cardiovascular prevention.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled